Jennifer W. Carlisle

Jennifer W. Carlisle

Hematology | Oncology

1365 Clifton Road Northeast
BldgC
Atlanta, GA 30322

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 46 publications

Real-World Implementation of Tarlatamab-Dlle Therapy for Patients With Extensive-Stage Small Cell Lung Cancer and Other High-Grade Neuroendocrine Neoplasms.

Real-World Implementation of Tarlatamab-Dlle Therapy for Patients With Extensive-Stage Small Cell Lung Cancer and Other High-Grade Neuroendocrine Neoplasms.

Journal: JCO oncology practice

Published: July 08, 2026

HSR26-256: Real-World Evidence of Predictors of Time to Amifampridine Discontinuation and Survival in Patients With Cancer-Associated and Non-Cancer-Associated Lambert-Eaton Myasthenic Syndrome in the United States.

HSR26-256: Real-World Evidence of Predictors of Time to Amifampridine Discontinuation and Survival in Patients With Cancer-Associated and Non-Cancer-Associated Lambert-Eaton Myasthenic Syndrome in the United States.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 16, 2026

HSR26-256: Real-World Evidence of Predictors of Time to Amifampridine Discontinuation and Survival in Patients With Cancer-Associated and Non-Cancer-Associated Lambert-Eaton Myasthenic Syndrome in the United States.

HSR26-256: Real-World Evidence of Predictors of Time to Amifampridine Discontinuation and Survival in Patients With Cancer-Associated and Non-Cancer-Associated Lambert-Eaton Myasthenic Syndrome in the United States.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: March 30, 2026

A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS.

A multi-institutional perspective on tarlatamab administration and management of CRS/ICANS.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 17, 2025

Survival Determinants and Sociodemographic Disparities in Early-Onset Non-Small Cell Lung Cancer.

Survival Determinants and Sociodemographic Disparities in Early-Onset Non-Small Cell Lung Cancer.

Journal: JAMA network open

Published: October 13, 2025

Real World Outcomes for the Efficacy and Safety of Osimertinib in Black Patients With Nonsmall Cell Lung Cancer.

Real World Outcomes for the Efficacy and Safety of Osimertinib in Black Patients With Nonsmall Cell Lung Cancer.

Journal: Clinical lung cancer

Published: September 29, 2025

Setting Expectations: Using Real-World Data to Guide Patients on Frontline Osimertinib.

Setting Expectations: Using Real-World Data to Guide Patients on Frontline Osimertinib.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: June 29, 2025

Taking a Bite Out of Small Cell Lung Cancer By Leveraging Precision-Directed Delta-Like Ligand-3 Therapies.

Taking a Bite Out of Small Cell Lung Cancer By Leveraging Precision-Directed Delta-Like Ligand-3 Therapies.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Published: May 29, 2025

Bispecific Antibodies in Non-Small Cell Lung Cancer: From Targeted Innovation to Real-World Integration.

Bispecific Antibodies in Non-Small Cell Lung Cancer: From Targeted Innovation to Real-World Integration.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Published: May 21, 2025

A Response to the Letter to the Editor: "Equipoise Is No Longer a Major Consideration in the Ethical Evaluation of Phase 3 Randomized Controlled Trials Involving Precision Oncology Approaches in NSCLC".

A Response to the Letter to the Editor: "Equipoise Is No Longer a Major Consideration in the Ethical Evaluation of Phase 3 Randomized Controlled Trials Involving Precision Oncology Approaches in NSCLC".

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: January 23, 2025

Safety and Tolerability of Lete-cel in NSCLC-Reply.

Safety and Tolerability of Lete-cel in NSCLC-Reply.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 17, 2025

Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy.

Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy.

Journal: ESMO open

Published: December 20, 2024

Showing 1-12 of 46

Last Updated: 09/26/2026